



Faggruppe for Organisk Kjemi (FOK)


Selective Synthesis in Chemical Biology

21. Organisk kjemiske høstmøte (OKH21)

21st National Autumn Meeting in Organic Chemistry

20.th of October 2017

Christiania Qvartalet Møtesenter, Oslo





Faggruppe for Organisk Kjemi (FOK)


Selective Synthesis in Chemical Biology

21. Organisk kjemiske høstmøte (OKH21)

21st National Autumn Meeting in Organic Chemistry

20.th of October 2017

Christiania Qvartalet Møtesenter, Oslo



21st National Autumn Meeting

09.00-09.25	Registration	
09.30-09.40	Opening remarks	Trond V. Hansen
09.40-10.40	Professor Petri Pihko University of Jyväskylä, Jyväskylä, Finland. <i>Can we design organocatalysts?</i>	Chair: Trond V. Hansen
10.40-11.40	Professor Stuart Conway University of Oxford, Oxford, UK <i>The Development of Potent CREBBP Bromodomain Ligands</i>	Chair: Bengt Erik Haug
11.40-12.00	Coffee and refreshments	
12.00-13.00	Professor Mercedes Amat University of Barcelona, Barcelona, Spain <i>Chiral Tricyclic Lactams as Multipurpose Scaffolds for the Efficient Synthesis of Decahydroquinoline alkaloids</i>	Chair: Anne Fiksdahl
13.00-13.45	Lunch	
13.45-14.45	Professor Soai Tokyo University of Science, Tokyo, Japan <i>Asymmetric Autocatalysis and the Origin of Homochirality</i>	Chair: Mohamed Amedjkouh
14.45-15.00	Coffee and refreshments	
15.00-16.00	Professor Karl-Heinz Altmann ETH Zürich, Zürich, Switzerland. <i>Total Synthesis and Functional Exploration of Bioactive Natural Macrocycles</i>	Chair: Annette Bayer
16.00-16.05	Concluding remarks	Trond V. Hansen

Organizing Committee

The Board of the Norwegian Chemical Society – Section for organic chemistry
(NKS-FOK):

Trond Vidar Hansen

Inger Reidun Aukrust

Annette Bayer

Anne Fiksdahl

Bengt Erik Haug

Associate committee member for OKH21

Mohamed Amedjkouh

Web address – <http://www.kjemi.no/organisk/>

Sponsors and exhibitors

Generous financial support from the following sponsors is greatly acknowledged:



ChemSupport AS



NERLIENS MESZANSKY



University of Oslo,
School of Pharmacy

Previous one-day symposia organized by NKS-FOK

- 1995 - OKH1** *Legemidler fra idé til produkt.* Nycomed Imaging, Oslo.
- 1996 - OKH2** *Nye trender i organisk syntese.* Nycomed Imaging, Oslo.
- 1997 - OKH3** *Research and Development in the Pharmaceutical Industry.* Nycomed Imaging, Oslo.
- 1998 - OKH4** *New Trends in Organic and Medicinal Chemistry.* Nycomed Imaging, Oslo.
- 1999 - OKH5** *Development of New Drugs.* Ingeniørenes Hus, Oslo.
- 2000 - OKVÅR1** *Application of Phase Transfer Catalysis (PTC) and Solvent Selection in Synthesis of Pharmaceutical Chemicals.* Ingeniørenes Hus, Oslo.
- 2000 - OKH6** *Development of Industrial Syntheses.* Ingeniørenes Hus, Oslo.
- 2001 - OKVÅR2** *Asymmetric Synthesis.* Ingeniørenes Hus, Oslo.
- 2002 - OKH7** *New Trends in Heterocyclic Chemistry.* Ingeniørenes Hus, Oslo.
- 2003 - OKH8** *New Trends in Bioorganic and Medicinal Chemistry.* Ingeniørenes Hus, Oslo.
- 2004 - OKH9** *New Technologies in Organic Synthesis.* Norges Varemesse, Lillestrøm. (Part of Det 17. Landsmøte i Kjemi).
- 2005 - OKH10** *New Trends in Organic and Organometallic Chemistry.* Ingeniørenes Hus, Oslo.
- 2006 - OKH11** *Organocatalysis.* Radisson SAS Airport Hotel, Gardermoen.
- 2007 - OKH12** *Organofluorine Chemistry.* Ingeniørenes Hus, Oslo.
- 2008 - OKH13** *Advanced Organic Materials.* Ingeniørenes Hus, Oslo.
- 2009 - OKH14** *Green Organic Chemistry.* Ingeniørenes Hus, Oslo.
- 2010** *OKH part of 18th International Conference on Organic Synthesis, ICOS-18, Bergen.*
- 2011 - OKH15** *OKH part of Landsmøtet, Norges Varemesse, Lillestrøm.*
- 2012 - OKH16** *Organic Chemistry in Bioprospecting and Molecular Gastronomi.* Christiania Qvartale Møtesenter, Oslo.
- 2013 - OKH17** *Novel Methods and Catalytic Reactions in Organic Chemistry.* Christiania Qvartale Møtesenter, Oslo.
- 2014 - OKH18** *OKH part of Landsmøtet, Norges Varemesse, Lillestrøm.*
- 2015 - OKH19** *New synthetic organic chemistry, reactive intermediates and drug development.* Christiania Qvartale Møtesenter, Oslo.
- 2016 - OKH20** *New Trends, Topics and methods in organic chemistry,* Christiania Qvartale Møtesenter, Oslo.

Abstracts


Can we design organocatalysts?

Petri M. Pihko


Department of Chemistry and NanoScience Center, University of Jyväskylä, Finland,
Petri.Pihko@jyu.fi

Keywords: organocatalysis, hydrogen bonding, noncovalent interactions, enantioselectivity, foldamers


Noncovalent interactions play very important roles in determining the enantioselectivities and rates of catalytic enantioselective reactions. In addition, the conformational preferences, or *folding* patterns in catalysts that can exist in different folds, may be important for selectivity and activity. In this talk, recent examples of enantioselective organocatalytic reaction and mechanistic insights into their design – or the prospects for their design – are discussed.^{1,2}



Example:



Application:



References

- [1] Probst, N.; Madarász, Á.; Valkonen, A.; Pápai, I.; Rissanen, K.; Pihko, P. M. *Angew. Chem. Int. Ed.*, **2012**, *51*, 8495-8499. b) Neuvonen, A. J.; Pihko, P. M. *Org. Lett.* **2014**, *16*, 5152-5155. c) Neuvonen, A. J.; Földes, T.; Madarász, Á.; Pápai, I. *ACS Catal.* **2017**, *7*, 3284-3294.
- [2] a) Kemppainen, E. K.; Sahoo, G.; Pihko, P. M. *Org. Lett.* **2012**, *14*, 1086-1089. b) Kemppainen, E. K.; Sahoo, G.; Piisola, A.; Hamza, A.; Kótai, B.; Pápai, I.; Pihko, P. M. *Chem. Eur. J.* **2014**, *20*, 5983-5993. c) Siitonen, J. H.; Pihko, P. M. *Synlett* **2014**, *25*, 1888-1890. d) Claraz, A.; Sahoo, G.; Berta, D.; Madarász, Á.; Pápai, I.; Pihko, P. M. *Angew. Chem. Int. Ed.*, **2016**, *55*, 669-673.

The Development of Potent CREBBP Bromodomain Ligands

Stuart J. Conway

Department of Chemistry, University of Oxford,
Oxford, UK

stuart.conway@chem.ox.ac.uk




Figure 1. (A) Histone tails are subjected to multiple PTMs, including lysine acetylation. Lysine acetylation state is “read” by bromodomains, protein modules that exist as part of a more complex protein architecture. cAMP response element-binding protein (CREB)-binding protein (CREBBP or CBP) is shown. (B) An X-ray crystal structure of the CREBBP bromodomain in complex with KAc (carbon = purple, PDB ID, 3P1C). (C) The KAc residue binds in a well-defined pocket and, in CREBBP, forms interactions with N1168 and Y1125.

Epigenetics, defined as “stably heritable phenotype resulting in changes in a chromosome without alterations in the DNA sequence”, comprises regulatory mechanisms of chromatin state that control access to DNA, mediated by noncoding RNA, DNA methylation, nucleosome remodelling histone variants, and some histone post-translational modifications (PTMs). Histone PTMs are dynamic, with cellular machinery identified that can add these modifications and that can remove them. A third class of proteins, termed “readers”, has been identified (Figure 1A), that binds to PTMs and thus stabilise large protein assemblies, which are often involved in transcriptional regulation. Bromodomains (Figure 2B), protein modules that act as readers of lysine acetylation state, have emerged as important therapeutic targets for a number of indications, especially in oncology.^{1,2} We have developed small molecule inhibitors of the bromodomain and extra terminal domain (BET) family of bromodomain-containing proteins,³⁻⁵ and the CREB-binding protein (CREBBP) bromodomain.^{6,7} Recent developments in the optimisation of these probes will be discussed, with a focus on the development of potent and selective CREBBP bromodomain ligands.

- (1) Hewings, D. S.; Rooney, T. P. C.; Jennings, L. E.; Hay, D. A.; Schofield, C. J.; Brennan, P. E.; Knapp, S.; Conway, S. J. *J. Med. Chem.* **2012**, *55*, 9393–9413.
- (2) Brand, M.; Measures, A. M.; Wilson, B. G.; Cortopassi, W. A.; Alexander, R.; Höss, M.; Hewings, D. S.; Rooney, T. P. C.; Paton, R. S.; Conway, S. J. *ACS Chem. Biol.* **2015**, *10*, 22–39.
- (3) Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppasetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. *J. Med. Chem.* **2011**, *54*, 6761–6770.
- (4) Hewings, D. S.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Picaud, S.; Tumber, A.; Wells, C.; Olcina, M. M.; Freeman, K.; Gill, A.; Ritchie, A. J.; Sheppard, D. W.; Russell, A. J.; Hammond, E. M.; Knapp, S.; Brennan, P. E.; Conway, S. J. *J. Med. Chem.* **2013**, *56*, 3217–3227.
- (5) Sekimik née Measures, A. R.; Hewings, D. S.; Theodoulou, N. H.; Jursins, L.; Lewendon, K. R.; Jennings, L. E.; Rooney, T. P. C.; Heightman, T. D.; Conway, S. J. *Angew. Chem. Int. Ed.* **2016**, *55*, 8353–8357.
- (6) Rooney, T. P. C.; Filippakopoulos, P.; Fedorov, O.; Picaud, S.; Cortopassi, W. A.; Hay, D. A.; Martin, S.; Tumber, A.; Rogers, C. M.; Philpott, M.; Wang, M.; Thompson, A. L.; Heightman, T. D.; Pryde, D. C.; Cook, A.; Paton, R. S.; Muller, S.; Knapp, S.; Brennan, P. E.; Conway, S. J. *Angew. Chem. Int. Ed.* **2014**, *53*, 6126–6130.
- (7) Hay, D. A.; Fedorov, O.; Martin, S.; Singleton, D. C.; Tallant, C.; Wells, C.; Picaud, S.; Philpott, M.; Monteiro, O. P.; Rogers, C. M.; Conway, S. J.; Rooney, T. P. C.; Tumber, A.; Yapp, C.; Filippakopoulos, P.; Bunnage, M. E.; Muller, S.; Knapp, S.; Schofield, C. J.; Brennan, P. E. *J. Am. Chem. Soc.* **2014**, *136*, 9308–9319.

Chiral Tricyclic Lactams as Multipurpose Scaffolds for the Efficient Synthesis of Decahydroquinoline alkaloids


Mercedes Amat

Laboratory of Organic Chemistry, Faculty of Pharmacy and Institute of Biomedicine (IBUB),
University of Barcelona, Av. Joan XXIII 27-31, 08028-Barcelona, Spain
amat@ub.edu


In the last years we have focused our attention on the development of new and efficient procedures for the enantioselective synthesis of nitrogen heterocycles with the final goal of applying them to the total synthesis of natural products and biologically active compounds. To this end, we originally explored a methodology based on the use of chiral, conformationally rigid and highly functionalized aminoalcohol-derived bicyclic lactams as enantiomeric scaffolds and carried out a systematic study on their scope and limitations for the enantioselective synthesis of nitrogen-derivatives.¹ As a result of this work, we have now in hand a flexible and versatile tool for the preparation of a broad range of chiral piperidines that allows the generation of new stereocenters with a high degree of stereoselectivity and a predictable absolute configuration. This methodology has enabled us to complete the enantioselective synthesis of a variety of piperidine-containing alkaloids, indole and oxindole alkaloids, and macrolactams. As an extension of this work, more recently, we have also reported the stereoselective generation of aminoalcohol-derived tricyclic lactams as chiral scaffolds for the preparation of *cis*-decahydroquinolines (DHQs) and octahydroindoles. The application of this methodology to the enantioselective synthesis of structurally diverse DHQ alkaloids will be discussed.²

Decahydroquinoline Alkaloids

Dendrobatid alkaloids (poison arrow frogs)




Pumiliotoxin C




Gephyrotoxin 287C

Alkaloids from plants




Cermizine B
(*Lycopodium*)




X = H, H Schoberine
X = O Myrionamide
(*Myrioneuron*)

Marine alkaloids



Lepadin B



Cylandricine A

- [1] C. Escolano, M. Amat, J. Bosch, *Chem. Eur. J.* **2006**, *12*, 8198; b) M. Amat, M. Pérez, J. Bosch, *Synlett* **2011**, *2*, 143; c) M. Amat, M. Pérez, J. Bosch, *Chem. Eur. J.* **2011**, *17*, 7724.
[2] a) Pinto, A.; Grier, R.; Molins, E.; Fernández, I.; Bosch, J.; Amat, M. *Org. Lett.* **2017**, *19*, 1714; b) Ghirardi, E.; Grier, R.; Picciché, M.; Fernández, I.; Bosch, J.; Amat, M. *Org. Lett.* **2016**, *18*, 5836; c) Amat, M.; Pinto, A.; Grier, R.; Bosch, J. *Chem. Eur. J.* **2015**, *21*, 12804.


Asymmetric Autocatalysis and the Origin of Homochirality

Kenso Soai

Department of Applied Chemistry, Tokyo University of Science,
Kagurazaka, Shinjuku-ku, Tokyo, Japan
soai@rs.kagu.tus.ac.jp

Asymmetric autocatalysis is a reaction in which chiral product acts as a chiral catalyst for its own formation. The process is a catalytic self-replication of chiral molecule, and has advantages over usual asymmetric catalysis: (1) because the product becomes catalyst, the amount of catalyst increases and no decrease in the catalytic activity, (2) because the structure of the asymmetric autocatalyst and the product is the same, no need to separate the product from catalyst.

We found asymmetric autocatalysis of enantiomeric excess of pyrimidyl alkanol in the enantioselective addition of diisopropylzinc to pyrimidine-5-carbaldehyde.¹ Significant amplification of ee is observed in the asymmetric autocatalysis. Starting from pyrimidyl alkanol with only ca. 0.00005% ee as asymmetric autocatalyst, pyrimidyl alkanol with >99.5% ee was formed in consecutive asymmetric autocatalysis.²



We have been studying the origin of homochirality by using asymmetric autocatalysis. Chiral inorganic crystal, chiral isotopomers,³ chiral crystals composed of achiral organic compounds, circularly polarized light (CPL), enantiotopic face of achiral mineral, i.e., gypsum,⁴ act as chiral triggers in asymmetric autocatalysis. Pyrimidyl alkanol of the corresponding absolute configuration with those of chiral triggers was obtained.

References


1. K. Soai, T. Shibata, H. Morioka, K. Choji, *Nature*, **1995**, 378, 767-768.
2. K. Soai, T. Kawasaki, A. Matsumoto, *Acc. Chem. Res.*, **2014**, 47, 3643-3654.
3. A. Matsumoto, H. Ozaki, S. Harada, K. Tada, T. Ayugase, H. Ozawa, T. Kawasaki and K. Soai, *Angew. Chem. Int. Ed.*, **2016**, 55, 15246-15249.
4. A. Matsumoto, Y. Kaimori, M. Uchida, H. Omori, T. Kawasaki, K. Soai, *Angew. Chem. Int. Ed.*, **2017**, 56, 545-548.

Total Synthesis and Functional Exploration of Bioactive Natural Macrocycles

Karl-Heinz Altmann

*ETH Zürich,
Zürich, Switzerland
karl-heinz.altmann@pharma.ethz.ch*

Macrocyclic secondary metabolites are a diverse group of bioactive natural products and many of these compounds have been, and continue to be important leads for drug discovery and development. This contribution will discuss selected aspects of the synthetic chemistry, medicinal chemistry and chemical biology of two macrocyclic natural products, the marine macrolide zampanolide (**1**) and the mycobacterial toxins mycolactones A/B (**2**). (-)-Zampanolide (**2**) is a microtubule-stabilizing agent (MSA) and it is a potent inhibitor of human cancer cell proliferation *in vitro*; mycolactones A/B (**2**) are produced by the human pathogen *M. ulcerans* and are the causative pathogenic agents for Buruli ulcer, but their molecular target(s) have not been elucidated.



We have developed efficient modular total syntheses for both of the above natural products. For **1**, macrocyclic ring-closure was based on an intramolecular Horner-Wittig-Emmons reaction between C8 and C9, which proceeded in high yield and with excellent selectivity. The same overall approach was employed in the synthesis of analogs of **1** for SAR studies. A high resolution crystal structure of the complex of **1** with tubulin has provided fundamentally new insights into the molecular mechanism of MSA-induced tubulin assembly. **2** was prepared *via* ring-closing olefin metathesis (RCM) as one of the key steps, followed by elaboration of the upper and lower side chain, respectively. Conjugates of **2** have been prepared that have allowed the exploration of the mechanistic pathways responsible for mycolactone toxicity.

List of participants

Altmann, Karl-Heinz

ETH Zürich

karl-heinz.altmann@pharma.ethz.ch

Amat Tuson, Maria Mercedes

University of Barcelona

amat@ub.edu

Amedjkouh, Mohamed

Universitetet i Oslo

mamou@kjemi.uio.no

Antonsen, Simen

NMBU

simen.antonsen@nmbu.no

Aukrust, Inger Reidun

Synthetica AS

ira@synthetica.no

Austli, Guro Buaas

NTNU

guroba@stud.ntnu.no

Balcells, David

Universitetet i Oslo

david.balcells@kjemi.uio.no

Bayer, Annette

Universitetet i Tromsø – Norges Arktiske

Universitet

annette.bayer@uit.no

Bero, Rawan

Universitetet i Oslo

rawanb@student.farmasi.uio.no

Bolsønes, Marianne

Forsvarets Forskningsinstitutt

marianne.bolsones@ffi.no

Boomgarden, Marc

Universitetet i Tromsø – Norges Arktiske

Universitet

marc.boomgarden@uit.no

Brondz, Anton

Synthetica AS

ab@synthetica.no

Conway, Stuart

University of Oxford

stuart.conway@chem.ox.ac.uk

Due-Hansen, Maria-Elisabeth

Forsvarets Forskningsinstitutt

maria-elisabeth.due-hansen@ffi.no

Espeseth, Ørjan

Matriks

orjan.espeseth@matriks.no

Eilertsen, Ingar

Teknolab AS

ie@teknolab.no

Fiksdahl, Anne

NTNU

anne.fiksdahl@chem.ntnu.no

Gammelsæter Johnson, Lars Inge

Universitetet i Oslo

l.i.g.johnsen@farmasi.uio.no

Garnås, Fredrik

NMBU

Fredrik.garnås@nmbu.no

Gjessing, Gard

NMBU

gard.gjessing@nmbu.no

Glessi, Christiano

Universitetet i Oslo

cristiano.glessi@smn.uio.no

Grøssereid, Ingrid

NTNU

ingridgrossereid@gmail.com

Hansen, Trond Vidar

Universitetet i Oslo

t.v.hansen@farmasi.uio.no

Halvorsen, Harald

ThermoFisher Scientific

harald.halvorsen@thermofisher.com

Halsvik, Beate

Universitetet i Bergen
beate.halsvik@uib.no

Haug, Bent Erik

Universitetet i Bergen
bengt-erik.haug@farm.uib.no

Hoff, Bård Helge

NTNU
bard.helge.hoff@chem.ntnu.no

Holmsen, Marte Sofie

Universitetet i Oslo
m.s.holmsen@kjemi.uio.no

Hofsløkken, Rune

Nerliens Meszansky AS
rune.hofslokken@nmas.no

Hoster, Norman Emanuel

NTNU
Norman.Hoster@uni-duesseldorf.de

Hustad, Jan Arild

ChemSupport AS
jah@chemsupport.no

Ihle Aarhus, Thomas

NTNU
thomas.i.aarhus@ntnu.no

Jacobsen, Øyvind

Oslo Universitets Sykehus
oyvind.jacobsen@farmasi.uio.no

Johannessen, Tonje

NMBU
Tonje.johannessen@nmbu.no

Johansson, Silje

Universitetet i Oslo
silje.johansson@farmasi.uio.no

Johansson Solum, Eirik

Nord universitet
eirik.j.solum@nord.no

Jørgensen, Kåre

Universitetet i Stavanger

kare.b.jorgensen@uis.no

Kampesæther, Arne

Nerliens Meszansky AS
arne.kampesaeter@nmas.no

Kania, Jindrich

ThermoFisher Scientific
jindrich.kania@thermofisher.com

Kildahl-Andersen, Geir

Universitetet i Oslo
geir.kildahl-andersen@farmasi.uio.no

Kjus, Nini Unn Hofsløkken

ThermoFisher Scientific
nini.kjus@thermofisher.com

Kristensen, Tor Erik

Forsvarets forskningsinstitutt
tor-erik.kristensen@ffi.no

Kristianslund, Renate

Universitetet i Oslo
renate.kristianslund@farmasi.uio.no

Levchenko, Vladimir

Universitetet i Oslo
volodymyr.levchenko@smn.uio.no

Madland, Marte Størdal

Thermo Fisher Scientific
marte.stordal@thermofisher.com

Mortansson Jelstrup Nolsøe, Jens

NMBU
jens.mj.nolsoe@nmbu.no

Neerbye Berntsen, Linn

Universitetet i Oslo
l.n.berntsen@kjemi.uio.no

Nesman, Jannicke Irene

Universitetet i Oslo
j.i.nesman@farmasi.uio.no

Olavesen, Ida Karoline

NMBU
ida.karoline.olavesen@nmbu.no

Pavlovic, Bojana
Universitetet i Oslo
bojanapavlovic83@gmail.com

Peeters, Sara
Universitetet i Oslo
sara.peeters@kjemi.uio.no

Pihko, Petri
University of Jyväskylä
petri.pihko@jyu.fi

Primdahl, Karoline
Universitetet i Oslo
k.g.primdahl@farmasi.uio.no

Ringheim-Bakka, Thomas Aleksander
BIOZEP AS
ta.bakka@biozep.com

Rongved, Pål
Universitetet i Oslo
pal.rongved@farmasi.uio.no

Rotunno, Giuseppe
Universitetet i Oslo

Schnaars, Christian
Universitetet i Oslo
Christian.schnaars@farmasi.uio.no

Soai, Kenso
Tokyo University of Science
soai@rs.kagu.tus.ac.jp

Solbakken, Erlend
Universitetet i Oslo
erlensau@kjemi.uio.no

Solli, Anders
NMBU
anders.solli@nmbu.no

Skotte, Christian
Chemical Abstract Services - ACS
cskotte@acs-i.org

Stenstrøm, Yngve

NMBU
yngve.stenstrom@nmbu.no

Suarez, Lluís Artus
Universitetet i Oslo
l.a.suarez@kjemi.uio.no

Suissa, Michal Rachel
Høgskolen i Oslo og Akershus
rachel.suissa@hioa.no

Tannæs, Bjørg Siw Møller
Høgskolen i Oslo og Akershus
bjorgm.tannas@hioa.no

Thoresen, Erik Mydske
Universitetet i Oslo
e.m.thoresen@kjemi.uio.no

Tilset, Mats
Universitetet i Oslo
mats.tilset@kjemi.uio.no

Torp Lien, Vegard
Universitetet i Oslo
v.t.lien@farmasi.uio.no

Trones, Roger
Teknolab AS
rt@teknolab.no

Tungen, Jørn Eivind
Universitetet i Oslo
j.e.tungen@farmasi.uio.no

Vik, Anders
Universitetet i Oslo
anders.vik@farmasi.uio.no

Wåhlander, Jakob
Universitetet i Oslo
j.k.k.wahlander@kjemi.uio.no

Åstrand, Alexander
Universitetet i Oslo
o.a.astrand@farmasi.uio.no

Norsk Kjemisk Selskap - Faggruppe for Organisk Kjemi

Innkalling til generalforsamling 2017

Sted: Skeikampen Høifjellshotell

Tid: Lørdag 13. januar 2018

Dagsorden:

1. Konstituering
2. Valg av møteleder og referent
3. Styrets årsberetning 2017
4. Regnskap 2017
5. Innkomne saker
6. Arrangør neste Organisk kjemisk vintermøte
7. Valg av styre, revisor og valgkomité

Saker som ønskes behandlet under punkt 5 må være styret i hende senest 2 uker før generalforsamlingen.

Oslo, 13.10.2017

Styret

Organisk kjemisk Vintermøte på Skeikampen Høifjellshotell

Faggruppen for organisk kjemi, Norsk Kjemisk Selskap, inviterer til det 33. Organisk kjemiske vintermøte - OKV 2018 - fra 11. til 14. januar 2018.

Inviterte foredragsholdere:

Professor Andreas Kirschning, Leibniz University of Hannover, Germany
Professor Valentine P. Ananikov, Zelinsky Institute of Organic Chemistry,
Russia

Professor Harry Anderson, University of Oxford, UK
Professor Tanja Gaich, University Konstanz, Germany

Praktiske opplysninger:

Program, informasjon om priser, transport, reisestipend og påmelding samt innsending av sammendrag av foredrag og plakater **er tilgjengelig** på møtets hjemmesider, se <http://www.kjemi.no/organisk/okv33/>.

Påmeldingsfrist er 1. Desember 2017. Ytterligere informasjon kommer på email.

Arrangør: Professor Bård Helge Hoff, NTNU, bard.helge.hoff@chem.ntnu.no

Get actionable results faster.



Less search. More research.

Accelerate discovery in your organization. Give your researchers streamlined access to highly relevant, actionable information that will propel your research program forward faster with confidence.

Built on our trusted collection of chemical research information, SciFinderⁿ sets a new standard with remarkably relevant search, incredible ease of use, and answers you can take right to the lab.

SciFinderⁿ A CAS SOLUTION

Search

Search by Substance Name, CAS RN, Patent Number, etc.

kinase inhibitors in the treatment of cancer

Advanced search for Molecular Formula

Recent Searches

October 2, 2017

10:06 AM

References: p38 MAP Kinase inhibitors in the treatment of cancer

As Drawn (3,103), Substructure (3,267)

September 25, 2017

Get actionable results faster with a streamlined new interface

- Add important chemical context to your keyword search with chemical structures
- Search all reactions, substances and references at once
- Living history lets you rerun past searches with a single click
- Unlimited use by everyone at your organization 24 x 7 x 365

Filter by

Relevance

Best (27)

Good (1,806)

Fair (0)

Learn more about Relevance...

Document Type

Journal (176)

Patent (1,833)

Review (463)

Conference (34)

Dissertation (8)

View All

Substance Role

Language

Publication Year

1990 to 2017

No Min to No Max (1,833)

View Larger

References (1,833)

Sort: Relevance View: Full Abstract

Substances Reactions Cited By Save

NF- κ B inhibitor-p38 MAP kinase inhibitor combination for the treatment of cancer and inflammatory diseases

By: Fu, Haijun; Liotta, Dennis C.; Thomas, Shala L.; Snyder, James P. World Intellectual Property Organization, WO2008150899 A1 2008-12-11 | Language: English, Database: CAplus View Reference Detail

Abstract: The invention is directed to combinations of compounds useful in the treatment and prevention of cancer and inflammatory conditions or diseases. In particular embodiments, the combinations comprise one or more compounds that are NF- κ B inhibitors or p38 MAPK inhibitors. The invention further provides pharmaceutical compositions and methods of treatment using the combinations. In one embodiment, the NF- κ B inhibitor is a curcumin analog.

Preparation of oxazolopyridinylimidazoles as p38 MAP kinase inhibitors useful in the treatment of cancer

By: Coates, David Andrew; Gilmore, Raymond; Martin, Jose Alfredo; Martin De La Nava, Eva Maria World Intellectual Property Organization, WO2012074761 A1 2012-06-07 | Language: English, Database: CAplus View Reference Detail

Abstract: The invention provides oxazolopyridinylimidazoles of formula I and their pharmaceutically acceptable salts as p38 MAP kinase inhibitors useful in the treatment of cancer. Compounds of formula I are methoxyethyl and

Relevant results right away

- Get the right results at first search with the best chemical inflammatory disease engine
- Powerful, comprehensive filters for rapid focus
- Results are displayed in a format designed for quick comprehension
- Quickly understand research velocity with publication trend analysis



SciFinderⁿ is a trademark of the American Chemical Society.



